The stratagraft market research report is one of a series of new reports that provides stratagraft market statistics, including stratagraft industry global market size, regional shares, competitors with a stratagraft market share, detailed stratagraft market segments, market trends, and opportunities, and any further data you may need to thrive in the stratagraft industry. This stratagraft market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to the rising incidence of diabetes and obesity, a growing aging population, increasing industrial accidents, higher adoption of bioengineered solutions, supportive government policies, growing healthcare infrastructure in emerging markets, and escalating prevalence of chronic wounds. Major trends in the forecast period include gradual adoption of skin substitutes, focus on reducing donor site morbidity, increasing clinical trials for bioengineered products, advancements in skin substitute technology, and advancements in burn care protocols.
The increasing prevalence of chronic wounds and burn injuries is expected to drive growth in the stratagraft market in the coming years. Chronic wounds occur when skin or underlying tissue is damaged and heals slowly due to conditions such as diabetes or poor circulation, while burn injuries can result from thermal, chemical, or electrical exposures and often require advanced medical interventions. Factors contributing to the rise in chronic wounds and burn injuries include the growing incidence of diabetes, obesity, an aging population, workplace accidents, and inadequate access to preventive care in many areas. Stratagraft offers a bioengineered solution for these injuries, providing an alternative to traditional skin grafts that promotes healing while minimizing the need for donor site procedures. According to the World Health Organization (WHO), approximately 180,000 deaths are caused by burns globally each year, with most occurring in low- and middle-income countries. In the United States alone, an estimated 410,000 burn injuries occurred in 2023, with about 40,000 requiring hospitalization, highlighting the ongoing public health challenge posed by burn injuries. This increasing incidence is fueling the growth of the stratagraft market.
The rise in clinical trials is also contributing to the expansion of the stratagraft market. Clinical trials are critical for assessing the effectiveness, safety, and potential side effects of medical treatments, and their increasing frequency reflects advancements in medical research and the growing complexity of healthcare needs. These trials play a crucial role in supporting stratagraft, providing valuable data on its safety and efficacy in treating severe burn injuries. This evidence is essential for validating its ability to enhance skin regeneration, reduce complications, and facilitate its approval for broader use in clinical settings. For example, in November 2023, the Association of the British Pharmaceutical Industry reported a 4.3% increase in the number of industry-sponsored clinical trials in the UK, from 394 trials in 2021 to 411 in 2022. This trend underscores the growing role of clinical trials in advancing medical treatments and, in turn, driving the growth of the stratagraft market.
Innovation in the development of stratagraft is another key factor enhancing its market potential. The focus is on creating allogeneic cultured keratinocytes and dermal fibroblasts embedded in murine collagen, which significantly improves wound healing and offers a promising alternative to autografts for treating severe burns and skin injuries. These biological constructs are specifically designed to accelerate skin regeneration and aid in wound healing. For instance, Mallinckrodt Pharmaceuticals developed StrataGraft, an innovative treatment for adults with deep partial-thickness thermal burns, which has been approved by the U.S. Food and Drug Administration. This product contains allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen and aims to reduce the need for autografting, which typically involves using a patient's own skin to close wounds.
The countries covered in the stratagraft market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
StrataGraft is a bioengineered skin substitute created to treat deep partial-thickness burns and other intricate skin injuries. It is made up of both epidermal and dermal layers, which are derived from human keratinocytes and dermal fibroblasts that are cultured on a collagen matrix.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
StrataGraft is primarily indicated for the treatment of thermal burns and full-thickness burns. Thermal burns occur when skin is exposed to heat sources such as flames, steam, or hot surfaces, leading to tissue and skin damage. The product’s formulations include cultured allogeneic keratinocytes and dermal fibroblasts, and it is used by hospitals, specialized wound care centers, and outpatient care facilities.
The stratagraft market consists of sales of bioengineered skin substitutes, dermal replacement Grafts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising incidence of diabetes and obesity, a growing aging population, increasing industrial accidents, higher adoption of bioengineered solutions, supportive government policies, growing healthcare infrastructure in emerging markets, and escalating prevalence of chronic wounds. Major trends in the forecast period include gradual adoption of skin substitutes, focus on reducing donor site morbidity, increasing clinical trials for bioengineered products, advancements in skin substitute technology, and advancements in burn care protocols.
The increasing prevalence of chronic wounds and burn injuries is expected to drive growth in the stratagraft market in the coming years. Chronic wounds occur when skin or underlying tissue is damaged and heals slowly due to conditions such as diabetes or poor circulation, while burn injuries can result from thermal, chemical, or electrical exposures and often require advanced medical interventions. Factors contributing to the rise in chronic wounds and burn injuries include the growing incidence of diabetes, obesity, an aging population, workplace accidents, and inadequate access to preventive care in many areas. Stratagraft offers a bioengineered solution for these injuries, providing an alternative to traditional skin grafts that promotes healing while minimizing the need for donor site procedures. According to the World Health Organization (WHO), approximately 180,000 deaths are caused by burns globally each year, with most occurring in low- and middle-income countries. In the United States alone, an estimated 410,000 burn injuries occurred in 2023, with about 40,000 requiring hospitalization, highlighting the ongoing public health challenge posed by burn injuries. This increasing incidence is fueling the growth of the stratagraft market.
The rise in clinical trials is also contributing to the expansion of the stratagraft market. Clinical trials are critical for assessing the effectiveness, safety, and potential side effects of medical treatments, and their increasing frequency reflects advancements in medical research and the growing complexity of healthcare needs. These trials play a crucial role in supporting stratagraft, providing valuable data on its safety and efficacy in treating severe burn injuries. This evidence is essential for validating its ability to enhance skin regeneration, reduce complications, and facilitate its approval for broader use in clinical settings. For example, in November 2023, the Association of the British Pharmaceutical Industry reported a 4.3% increase in the number of industry-sponsored clinical trials in the UK, from 394 trials in 2021 to 411 in 2022. This trend underscores the growing role of clinical trials in advancing medical treatments and, in turn, driving the growth of the stratagraft market.
Innovation in the development of stratagraft is another key factor enhancing its market potential. The focus is on creating allogeneic cultured keratinocytes and dermal fibroblasts embedded in murine collagen, which significantly improves wound healing and offers a promising alternative to autografts for treating severe burns and skin injuries. These biological constructs are specifically designed to accelerate skin regeneration and aid in wound healing. For instance, Mallinckrodt Pharmaceuticals developed StrataGraft, an innovative treatment for adults with deep partial-thickness thermal burns, which has been approved by the U.S. Food and Drug Administration. This product contains allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen and aims to reduce the need for autografting, which typically involves using a patient's own skin to close wounds.
The key company operating in the stratagraft market is Mallinckrodt Pharmaceuticals plc
North America was the largest region in the stratagraft market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stratagraft report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the stratagraft market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
StrataGraft is a bioengineered skin substitute created to treat deep partial-thickness burns and other intricate skin injuries. It is made up of both epidermal and dermal layers, which are derived from human keratinocytes and dermal fibroblasts that are cultured on a collagen matrix.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
StrataGraft is primarily indicated for the treatment of thermal burns and full-thickness burns. Thermal burns occur when skin is exposed to heat sources such as flames, steam, or hot surfaces, leading to tissue and skin damage. The product’s formulations include cultured allogeneic keratinocytes and dermal fibroblasts, and it is used by hospitals, specialized wound care centers, and outpatient care facilities.
The stratagraft market consists of sales of bioengineered skin substitutes, dermal replacement Grafts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. StrataGraft Market Characteristics4. StrataGraft Market Trends And Strategies5. StrataGraft Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global StrataGraft Pricing Analysis & Forecasts30. Global StrataGraft Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The StrataGraft Market32. Recent Developments In The StrataGraft Market
3. StrataGraft Market Biologic Drug Characteristics
6. Global StrataGraft Growth Analysis And Strategic Analysis Framework
8. StrataGraft Market Segmentation
9. Global StrataGraft Epidemiology Of Clinical Indications
10. StrataGraft Market Regional And Country Analysis
11. Asia-Pacific StrataGraft Market
12. China StrataGraft Market
13. India StrataGraft Market
14. Japan StrataGraft Market
15. Australia StrataGraft Market
16. South Korea StrataGraft Market
17. Western Europe StrataGraft Market
18. UK StrataGraft Market
19. Germany StrataGraft Market
20. France StrataGraft Market
21. Eastern Europe StrataGraft Market
22. North America StrataGraft Market
23. USA StrataGraft Market
24. Canada StrataGraft Market
25. South America StrataGraft Market
26. Middle East StrataGraft Market
27. Africa StrataGraft Market
28. StrataGraft Market Competitive Landscape And Company Profiles
29. Global StrataGraft Market Pipeline Analysis
33. StrataGraft Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
StrataGraft Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on stratagraft market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for stratagraft ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The stratagraft market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Thermal Burns; Full-Thickness Burns2) By Formulation: Allogeneic Cultured Keratinocytes; Dermal Fibroblasts
3) By End User: Hospitals; Specialized Wound Care Centers; Outpatient Care
Key Companies Profiled: Mallinckrodt Pharmaceuticals plc
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Mallinckrodt Pharmaceuticals plc